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ABSTRACT
Introduction: Giant cell arteritis (GCA) is a
chronic vasculitis affecting approximately
230,000 Americans. Limited data exist on the
healthcare resource utilization and costs
attributable to GCA. The objective of this
study was to estimate the cost of illness in
patients with GCA in the US.
Methods: A cohort of patients with a new GCA
diagnosis was identified from a large US claims
database between 1 January 2008 and 31
December 2012. Newly diagnosed GCA
patients were defined by two claims with GCA
(ICD-9 446.5) as one of the listed diagnoses
during the study period and no GCA diagnosis
in the 12 months prior. Subjects without a GCA
diagnosis were matched 5:1 to cases. One-year
healthcare costs were compared among cases
and controls, adjusting for covariates using
generalized linear models.
Results: A cohort of 1293 GCA patients and
6465 controls was identified. The mean age was
73 years, and 69% were females. Mean Charlson
Comorbidity Index was 1.9 for GCA patients
and 1.0 for controls. Mean 1-year cost for GCA
patients was $34,065 [standard deviation (SD)
$52,411], and mean 1-year cost for controls was
$12,890 (SD $37,345). After multivariate
adjustment, the difference in 1-year cost
between GCA patients and controls was
$16,431 (95% CI $13,821–$19,041).
Conclusions: Patients with GCA experience
substantially higher healthcare costs in the
first year following diagnosis compared to
patients without GCA. These results add to the
limited evidence available to inform
researchers, clinicians, and policymakers on
the cost burden of GCA in the US.
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INTRODUCTION
Giant cell arteritis (GCA)—also known as
temporal arteritis, cranial arteritis, or Horton’s
disease—is a widespread chronic vasculitis of
large and medium blood vessels. Symptomatic
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inflammation usually involves the blood vessels
of the head and neck that originate from the
external carotid artery, the ascending aortic arch,
and the descending aorta [1]. GCA may present
with systemic symptoms such as fever, but the
most common symptom is temporal or occipital
headache accompanied by scalp tenderness [2].
The arterial blockage associated with GCA leads
to ischemic symptoms such as jaw claudication,
intermittent claudication of the tongue and the
muscles involved in swallowing, and rarely
infarction of the scalp or the tongue [2]. Thirty
percent of patients have partial visual loss that
may rapidlyprogress toblindness if untreated [3].
Some patients may develop neurological
complications (e.g., stroke), respiratory
problems, musculoskeletal manifestations, and
large artery aneurysms [2, 4].
GCA is more common in Caucasian
populations of Scandinavian descent, is more
common in women, and is rare in individuals
under 50 years [5, 6]. The annual incidence of
GCA in the US is estimated to be 18.9 per
100,000 [7], and the estimated prevalence is 228
per 100,000 [8]. It is estimated that nearly
950,000 individuals will be diagnosed with
GCA and 140,000 will become visually
impaired because of GCA in the US between
2014 and 2050 [9]. Visual impairment takes the
form of blurred vision or complete visual
impairment but can be reversible: among
patients with complete visual impairment,
75% achieve full resolution within 3 months,
but resolution is less likely with complete visual
impairment compared to blurred vision [10].
According to the traditional American
College of Rheumatology (ACR) clinical
classification criteria, a diagnosis of GCA is
present when three of five criteria are met [11].
These clinical criteria may be supported by other
laboratory and radiological tests to identify and
manage a wide range of complications.
The mainstay of GCA clinical management is
high-dose corticosteroids, typically
prednisolone, with prolonged treatment, slow
tapering, and close monitoring [12]. Some
physicians use aspirin, although its benefit has
not been proven. Use of steroids is associated
with the development of diabetes, hypertension,
osteopenia, osteoporosis, fractures, and
cataracts. Calcium supplements, vitamin D
supplements, and bisphosphonates are typically
given to patients with reduced bone mineral
density because of chronic steroid use. The
cytotoxic agent methotrexate has been used as
a corticosteroid-sparing drug in patients with
GCA with mixed results [13–15]. There is
currently no effective screening method or
definitive treatment for GCA. However, a
fast-track approach, relying on quick
ultrasonographic and clinical evaluation and
treatment initiation, has been shown to
significantly reduce the risk of visual
impairment and the costs of treatment by
reducing inpatient healthcare utilization [16].
GCA causes significant morbidity,
particularly because of vision loss. A study
published in 2000 estimated that GCA was a
major contributor to the $150 million in annual
hospitalization costs associated with vasculitis
in the US [17]. A more recent model-based study
estimated that between 2014 and 2050, the
financial burden associated with GCA-related
visual impairment and steroid-related fractures
alone (due to side effects of GCA treatment)
would reach $77 billion and $6.6 billion,
respectively, in the US.
The projected financial burden of
GCA-related visual loss and steroid-related
adverse events among GCA patients in the US
in the coming decades will be substantial [9], but
there are limited data on the healthcare resource
utilization and costs that are attributable to a
GCA diagnosis overall. To contribute to the
evidence base, we estimated the cost of illness




We used administrative claims data from the
Truven Health Analytics MarketScan databases
(commercial and Medicare supplemental) for
the years 2007–2013 [18]. These databases,
consisting of fully adjudicated and paid
claims, capture person-specific clinical
utilization, expenditures, and enrollment
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across inpatient, outpatient, and prescription
drug services. The commercial database
includes members of the working population
under age 65 from over 100 contributing large
employers and their dependents. The Medicare
supplemental database contains the healthcare
experience of individuals with Medicare
supplemental insurance paid by their
employers. The two components cover
approximately 40 million lives and constitute
a nationally representative sample of Americans
with employer-provided health insurance. The
study was reviewed and approved by the
Institutional Review Board at the University of
Washington. This article does not contain any
new studies with human or animal subjects
performed by any of the authors.
Study Population
We identified patients with at least two medical
claims with GCA [International Classification of
Diseases, 9th Revision, Clinical Modification
(ICD-9-CM) code: 446.5] as one of the listed
diagnoses between 1 January 2008 and 31
December 2012. We defined the index date for
a GCA patient as the date of the first appearance
of the ICD-9 code in a calendar year. Additional
eligibility criteria included: (1) age 50 years or
older; (2) no GCA diagnosis 12 months prior to
the index date (incident GCA cases); (3) at least
one oral corticosteroid prescription filled within
6 months before or after the index date; (4)
continuous enrollment 12 months before
(baseline period) and 12 months after
(follow-up period) the index date. We included
enrollees from the same year who did not have a
GCAdiagnosis as potential controls.Weassigned
an index date to each potential control, defined
as a random date in the year of interest. We
applied the same eligibility criteria to the
potential controls and matched them to GCA
cases by a 5:1 ratio on age, sex, region (of the US),
and calendar year.
Outcomes and Covariates
We evaluated the following baseline
demographic and clinical characteristics: age,
sex, region, Charlson Comorbidity Index (CCI)
score [19], and type of health plan. We
calculated baseline CCI using inpatient and
outpatient claims from the 12-month period
prior to the index date. We examined the
following cost outcomes at 1 year after the
index date: total costs, inpatient costs,
outpatient costs, and pharmacy costs. The
estimated costs reflect the total amount paid
to all providers including paid claims from
insurers and out-of-pocket payments. We
adjusted all costs to the 2015 value using the
US consumer price index medical component
[20]. We also assessed cumulative corticosteroid
use and duration.
STATISTICAL ANALYSIS
We summarized continuous variables using
means with standard deviations (SD) and
categorical variables using percentages. We
compared the distributions of the
characteristics that were not matched (CCI
and type of health plan) between GCA cases
and controls using the chi-square test. We
compared 1-year total, inpatient, outpatient,
and pharmacy costs between GCA patients and
controls using a generalized linear model with
log link and gamma error distribution [21–23],
controlling for age (linear and quadratic), sex,
US region, index year, CCI category (0, 1, 2, 3?),
and health plan type (managed care vs.
non-managed care). Due to the large
proportion of patients with no reported
inpatient use, we used a two-part model [24]:
the first part was a logistic regression estimating
the probability of having non-zero costs, and
the second part was a generalized linear model
(GLM) estimating the mean costs among those
with non-zero costs. We also fit extended
estimating equation (EEE) models [25] as an
alternative (sensitivity analysis) to the GLMs.
We used the CCI to adjust for comorbidities
in all regression analyses. We also adjusted for
matched variables in all regression analyses to
avoid the bias associated with the presence or
absence of additional confounders [26].
We calculated the cost differences and
confidence intervals between GCA patients
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and controls by using recycled prediction and
bootstrapping the original sample 500 times. All
costs are presented in 2015 US dollars.
We estimated the cumulative dose of oral
corticosteroids and the difference in cumulative
dose and proportions of GCA cases and controls
who had steroids prescribed. We estimated the
cumulative dose and cumulative duration (in
days) for the supply of steroids prescribed. We
calculated the cumulative dose by multiplying
the steroid strength, the metric quantity, and
the prednisone conversion factor [27].
Statistical analyses were performed in Stata
MP13 (StataCorp, College Station, TX). This
article does not contain any new studies with
human or animal subjects performed by any of
the authors.
Data Availability
The data sets generated during and/or analyzed
during the current study are not publicly
available because they are commercial and
proprietary.
RESULTS
Study Population and Demographic
Characteristics
We identified 1293 eligible GCA patients in the
database from 2008 to 2012 and 6465 matched
controls. Demographic and clinical
characteristics are summarized in Table 1. The
distributions of age, sex, and region were
balanced between cases and controls after
matching; all cases were successfully matched.
The mean age was 73.3 years (SD 9.6 years). The
study population was predominantly female
(69%). A slightly higher percentage of the study
population was from the North Central part
(28.3%) or the South (28.5%) of theUS compared
to the Northeast (24.0%) and the West (18.6%).
Clinical Characteristics
GCA patients had significantly more
comorbidities compared to controls. The
percentages of GCA patients who had a CCI of
one, two, and three or greater were 30, 18, and
30%, respectively, compared to 22, 13, and 14%
for controls (P\0.001). Sixteen percent of GCA
patients were enrolled in a managed care plan
compared to one percent among controls.
Costs
The mean 1-year unadjusted total, inpatient,
outpatient, and pharmacy costs were higher for
GCA patients than for controls (Table 2). The
mean 1-year total, inpatient, outpatient, and
pharmacy costs were significantly higher for
GCA patients than for controls after adjusting
for age, sex, comorbidity, health plan type,
region, and calendar year (Table 2). A diagnosis
ofGCAwas associatedwith$16,400 in additional
costs for patients in the first year following
diagnosis. A diagnosis of GCA was associated
with over $5000 in additional inpatient costs,
over $10,000 in additional outpatient costs, and
$660 in additional pharmacy costs in the first
year following diagnosis.
Steroid Use
The cumulative quantity of steroids prescribed
was higher for GCA cases (4862 mg; SD 8620)
than controls (666 mg; SD 1192). The
cumulative duration (in days) for the supply of
steroids was higher for GCA cases (250; SD 163)
than controls (57, SD 113).
DISCUSSION
Using a national sample of administrative
medical claims, we demonstrated the
substantial cost impact of GCA in the US. We
estimated that a diagnosis of GCA is associated
on average with $16,400 in additional costs for
patients in the first year following diagnosis in
the US. We estimated that during the first year,
a diagnosis of GCA is associated on average with
over $5000 in additional inpatient costs, over
$10,000 in additional outpatient costs, and
$660 in additional pharmacy costs. However,
the results may not be generalizable to the
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entire population of GCA patients because
Medicare patients with supplemental coverage
may be different from Medicare patients
without supplemental coverage.
The estimated total cost associated with GCA
in the first year following diagnosis in the US is
higher than the first-year cost associated with
non-cystic fibrosis bronchiectasis ($2300) [28],
systemic lupus erythematosus ($6800) [29], and
endometriosis ($9500) [30], but lower than the
first-year cost associated with breast cancer
($42,400) [31]. Given the annual incidence of
18.9 GCA cases per 100,000 population in the
US [7, 32], the first-year aggregate cost of GCA
following diagnosis is estimated to be nearly
one billion dollars in the US.
A recent model-based study presented
estimates of the projected financial burden
Table 1 Characteristics of the study population
GCA patients (n 5 1293) Controls (n5 6465) p value
Age, years (SD) 73.3 (9.6) 73.3 (9.6) N/A
Female (%) 69.0 69.0 N/A
Charlson Comorbidity Index





3 and above 30.3 13.6
Plan type (%) \0.001
Comprehensive 37.9 28.1
Exclusive provider organization 0.2 0.0
Managed care 15.7 1.0
Non-capitated POS 3.3 4.2
PPO 42.4 66.3
Capitated or part-capitated POS 0.3 0.1
Consumer-driven health plan 0.1 0.1
High-deductible health plan 0.2 0.1
Region (%) N/A
Northeast 24.0 24.0




GCA giant cell arteritis, SD standard deviation, POS point of service, PPO preferred provider organization, N/A not
applicable
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associated with long-term GCA complications
from 2015 to 2050: nearly $77.5 billion for
visual impairment and over $6.6 billion for
steroid-induced fractures alone, resulting in a
total of $84 billion [9]. Our study adds to the
evidence of the economic burden associated
with GCA in the US by demonstrating that
there are substantial additional costs early in
the disease process.
We estimated a statistically significant
increase in inpatient, outpatient, pharmacy,
and total costs for patients with GCA during
the first year following diagnosis compared to
controls. The increase in pharmacy costs was
comparatively modest, which is not surprising,
given the recent diagnosis of GCA, and the fact
that steroids, the mainstay of GCA therapy, are
relatively inexpensive.
During the 1-year period of our analysis, the
quantity of steroids prescribed and length of
steroid use were higher in patients with GCA.
This may partly explain the large increase in
inpatient, outpatient, and total costs but only
modest increase in pharmacy costs associated
with GCA. Published research has shown that
even short-term corticosteroid use is associated
with increased risk of adverse outcomes, such as
osteoporosis, fractures, diabetes, and serious
infections [33–36]. According to the American
College of Rheumatology (ACR) 2010
recommendations for the prevention and
treatment of glucocorticoid-induced
osteoporosis, bone mineral density declines
rapidly within the first 3 months of
corticosteroid use and peaks at 6 months. One
large matching study compared 244,235
patients who used oral corticosteroids (of
whom 40% had respiratory disease) with the
same number of controls and followed them for
an average 1.3 years [36]. The authors reported a
dose-dependent increase in risk of fractures, i.e.,
a relative risk of 1.77 for hip fracture for users
with standardized daily doses of 2.5–7.5 mg
compared to controls, which increased to 2.27
for doses[7.5 mg. Further research is warranted
to assess the cost of adverse outcomes associated
with corticosteroid use in GCA.
The patients with GCA in our study also had
a significantly higher CCI than controls.
Although we adjusted for confounding by
another comorbidity using the CCI category in
multivariate analyses, residual confounding
may be present because of a variety of factors
such as unmeasured confounders or inadequate
adjustment; also, other chronic conditions may
have been misclassified as GCA, given the wide
variation in GCA clinical manifestations
[37–39].
Our study had a number of limitations. First,
we estimated the cost of illness for an incident
cohort of GCA patients over a short-term
(1 year) period and not a lifetime. A lifetime
approach might be preferred by some
stakeholders, for example, to estimate the
potential effect of a preventive intervention.
Second, there might be residual confounding in
our estimate of the cost attributable to GCA
given the limited set of variables available in a
commercial claims database. Third, given our
method of case identification, it is possible that
Table 2 Mean costs and adjusted cost differences by category
1-Year costs 1-Year costs*, mean (SD) Cost difference, mean (95% CI)
GCA patients (n5 1293) Controls (n5 6564)
Total $34,065 ($52,411) $12,890 ($37,345) $16,431 ($13,821–$19,041)
Inpatient $10,190 ($29,601) $3004 ($11,120) $5139 ($3821–$6457)
Outpatient $19,371 ($31,938) $6850 ($32,878) $10,389 ($8769–$12,009)
Pharmacy $4524 ($5638) $3034 ($5730) $663 ($344–$982)
GCA giant cell arteritis, SD standard deviation
* Unadjusted
 Adjusted for age (linear and quadratic), sex, chronic comorbidity index category, plan type (managed care or other),
region, and calendar year
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we may have misclassified individuals as newly
diagnosed with GCA. Finally, we may have
underestimated the cost of GCA because we
only estimated the direct costs that are captured
in a claims database. Indirect costs such as the
costs of informal care for GCA complications
and lost productivity were not included; these
costs could be included in future studies.
CONCLUSIONS
In conclusion, patients with GCA experience
substantially higher healthcare costs in the first
year of diagnosis compared to patients without
GCA after adjusting for covariates related to
healthcare resource utilization and costs. Our
study adds to the limited evidence on the
substantial cost of GCA and provides a
real-world estimate of the early costs of GCA
to complement previous model-based estimates
of the chronic cost of GCA in the US. Results of
our study are relevant and may be useful to
researchers, policymakers, and clinicians who
may need to understand or project the potential
impact of new interventions for GCA in their
respective settings.
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